IRVINE, Calif. and BRISBANE, Australia, Feb. 21, 2011 /PRNewswire/ -- Mater Children's Hospital and Masimo (Nasdaq: MASI) today jointly announce the conversion of Mater Children's Hospital to Masimo rainbow® SET Pulse CO-Oximetry™ technology for advanced noninvasive patient monitoring capabilities. The conversion equips the tertiary facility with the most technologically and clinically-advanced oximetry and noninvasive patient monitoring solutions available.
Masimo rainbow® SET Pulse CO-Oximetry is the first-and-only technology platform that allows hospitals to noninvasively measure and continuously monitor blood constituents and physiological parameters that previously required invasive procedures—including: total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRa™), in addition to the 'gold-standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR). The oximetry standard-of-care at leading hospitals worldwide, Masimo rainbow® SET provides immediate real-time results that enable clinicians to more rapidly assess patients and detect and treat adverse, potentially life-threatening conditions earlier.
"Converting to Masimo rainbow® SET provides our clinicians with superior patient monitoring capabilities and advanced clinical measurements thereby ensuring that our clinicians have access to quality clinical data," stated Malcolm Thatcher, Chief Information Officer for Mater Health Services. "The decision to standardize on Masimo's technology platform across our pediatric services was driven by the knowledge that, in harnessing the advanced noninvasive capabilities of Masimo rainbow® SET measurements, Mater is able to deliver an exceptional level of care and safety to our pediatric patients while recognizing the importance of the patient experience and supporting our organization's commitment to putting the patient first."
A major referral center for specialty pediatric healthcare services in Queensland, Mater Children's Hospital provides a range of inpatient, outpatient, and emergency care to over 167,000 children a year. The conversion ensures that all multiparameter patient monitors, stand-alone oximeters, and sensors feature the advanced noninvasive patient monitoring capabilities of Masimo rainbow® SET—allowing clinicians to easily and painlessly obtain and continuously track vital blood and physiological data for patients in real-time, anywhere in the hospital.
Mater Children's Hospital Pediatric Sleep Scientist, Gordon Williams, said the Sleep Unit relies on Masimo SET's ability to measure oxygen saturation during movement, which he says is "especially important in a pediatric facility where motion-artifact can be a major source of oximeter signal noise. Not only does Masimo's technology allow us to obtain more reliable saturation trend data in children being investigated in the sleep laboratory, but we are able to confidently use the Masimo Radical-7 Pulse CO-Oximeter as a screening and assessment tool on the wards as well. And in terms of future needs, Masimo's rainbow® SET Pulse CO-Oximetry platform positions us for growth well beyond how oximeters have traditionally been used to date."
Masimo Founder and CEO, Joe Kiani, stated, "Reducing the trauma of invasive tests and procedures for pediatric patients has long been a concern for every clinician and parent that cares for a sick child. Today, thanks to medical advancements enabled by Masimo rainbow® SET Pulse CO-Oximetry and the forward-thinking efforts of Mater Children's Hospital, pain-free hemoglobin testing and clinically reliable pulse oximetry is now a reality for pediatric patients in Queensland."
About Mater Children's Hospital
Mater Children's Hospital is a major tertiary pediatric referral centre with the busiest pediatric emergency department in Queensland. The hospital provides specialty healthcare services to more than 15,000 inpatient, 120,000 outpatient, and 32,000 emergency patients each year. To learn more about Mater, visit www.mater.org.au/Home/Hospitals/Mater-Children-s-Hospital.
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care . . . by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that the hospital-wide conversion ensures that all Mater Children's Hospital patients will be cared for using the most technologically and clinically-advanced noninvasive patient monitoring solutions available; risks related to our belief that Masimo rainbow SET provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our belief that SpHb detects low or falling hemoglobin levels that could be the result of internal bleeding; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care . . . by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, Pulse CO-Oximetry, Pulse CO-Oximeter, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pronto-7, Pronto, Patient SafetyNet, and SEDLine are trademarks or registered trademarks of Masimo Corporation.